Special Access Program (SAP)
Our Approach
We invite clients to consider the potential benefits of the SAP program as a pathway to access Psilocybin and MDMA therapies in Canada. While these treatments have not yet received official approval from Health Canada, the SAP offers a unique opportunity for those facing challenging health conditions.
To qualify for the SAP program, healthcare providers will need to submit an application on behalf of their patients. Patients themselves should have a serious or life-threatening condition and have explored all available conventional treatment options, which may not have yielded the desired results or may have been unsuitable for their specific situation. The SAP is designed to assist individuals who have exhausted these options and are seeking alternative solutions.
We encourage interested clients to explore the SAP program as a potential avenue to access innovative therapies that may offer relief and hope in their healthcare journey.
Advantages
Compared to tobacco/nicotine, alcohol, and caffeine, classic psychedelics have an exceptional safety profile for users.
MDMA and psilocybin are among the lowest risk endogenous compounds commonly consumed today.
Treatment Applications
MDMA has garnered significant attention for its promising therapeutic potential in addressing specific mental health conditions, with a particular focus on post-traumatic stress disorder (PTSD). The research surrounding MDMA’s use in therapy offers hope for those seeking innovative treatment options.
Psilocybin has shown remarkable promise particularly in the treatment of mood disorders such as treatment-resistant depression. Psilocybin-assisted therapy has demonstrated the potential to provide meaningful and enduring relief, surpassing current standard treatment approaches.
